Deep learning on meta-analytic data for therapeutic decision-making in central nervous system aspergillosis

利用深度学习进行荟萃分析数据在中枢神经系统曲霉病治疗决策中的应用

阅读:2

Abstract

BACKGROUND: Central nervous system (CNS) aspergillosis is a rare but highly fatal infection, particularly among immunocompromised individuals. Timely diagnosis and optimal treatment selection are crucial for improving patient outcomes, yet clinical decision-making remains challenging. METHODS: We integrated clinical data from 64 published CNS aspergillosis cases (2014–2024) and structured electronic medical records (EMRs) from 200 ICU patients. After preprocessing (one-hot encoding, Z-score standardization, BERT-based text feature extraction), a Gradient Boosting Classifier (GBC) was trained to predict 30-day survival. Additionally, a LinUCB-based adaptive treatment policy was developed to dynamically optimize therapy choices. Model performance was evaluated against logistic regression, random forest models, and baseline treatment policies. RESULTS: In a retrospective cohort of 64 patients, the contextual LinUCB policy outperformed ε-greedy and a random recommender, achieving the highest average predicted survival rate of 76.5% (max 83.0%, min 67.0%) versus 56.7% for ε-greedy and 49.3% for Random; the observed survival under clinician decisions was 50%. Feature ablation demonstrated that removing sex, clinical presentation, and imaging findings reduced the estimated survival by 19.6% points from an 83.3% baseline, whereas other features (e.g., age, country) each had smaller effects (< 10% points). The LinUCB adaptive policy demonstrated superior cumulative survival gain compared to random and ε-greedy strategies, indicating that incorporating patient context materially improves treatment recommendations. CONCLUSION: Integrating meta-analytic and EMR-derived data with machine learning models can accurately predict survival and inform adaptive treatment strategies in CNS aspergillosis. The proposed LinUCB-guided approach offers a promising framework for real-time, personalized decision-making in critically ill patients. CLINICAL TRIAL REGISTRATION: Not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-026-12573-7.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。